AI Article Synopsis

  • GABA transporters, specifically GAT-1, play a complex role in neuronal inhibition, and can reverse under certain conditions, which is typically not well understood.
  • Using experimental methods, it was demonstrated that GAT-1 can rapidly release GABA during action potentials when physiological conditions are met.
  • The study found that while traditional methods to block vesicular release did not hinder GABA transmission, GAT-1 antagonists effectively blocked this process, suggesting that GAT-1 is crucial in maintaining ambient GABA levels for neurotransmission.

Article Abstract

GABA transporters play an important but poorly understood role in neuronal inhibition. They can reverse, but this is widely thought to occur only under pathological conditions. Here we use a heterologous expression system to show that the reversal potential of GAT-1 under physiologically relevant conditions is near the normal resting potential of neurons and that reversal can occur rapidly enough to release GABA during simulated action potentials. We then use paired recordings from cultured hippocampal neurons and show that GABAergic transmission is not prevented by four methods widely used to block vesicular release. This nonvesicular neurotransmission was potently blocked by GAT-1 antagonists and was enhanced by agents that increase cytosolic [GABA] or [Na(+)] (which would increase GAT-1 reversal). We conclude that GAT-1 regulates tonic inhibition by clamping ambient [GABA] at a level high enough to activate high-affinity GABA(A) receptors and that transporter-mediated GABA release can contribute to phasic inhibition.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2156040PMC
http://dx.doi.org/10.1016/j.neuron.2007.10.021DOI Listing

Publication Analysis

Top Keywords

gat-1
5
nonvesicular inhibitory
4
inhibitory neurotransmission
4
reversal
4
neurotransmission reversal
4
gaba
4
reversal gaba
4
gaba transporter
4
transporter gat-1
4
gat-1 gaba
4

Similar Publications

Introduction: Geraniol (Ger), a monoterpene, is a common constituent of several essential oils. This study explored the anticonvulsant effect of Ger in-vitro using nerve growth factor (NGF) prompted PC12 cell injured by Glutamate (Glu) and in-vivo using Pentylenetetrazole (PTZ)-induced kindling through the GABAergic pathway.

Materials: To assess the effect of Ger on NGF prompted PC12 cells injured by Glu, Ger at concentrations of 25, 50, 100, 200 and 400 μg/mL was used.

View Article and Find Full Text PDF

The SLC6A1 gene encodes the gamma-aminobutyric acid (GABA) transporter GAT-1, the deficiency of which is associated with infantile encephalopathy with intellectual disability. We designed two AAV9 vectors, with either the JeT or MeP promoter, and conducted preclinical gene therapy studies using heterozygous and homozygous Slc6a1 KO mice at different developmental ages and various routes of administration. Neonatal intracerebroventricular administration of either vector resulted in significantly normalized EEG patterns in Slc6a1-/- or Slc6a1+/- mice, as well as improvement in several behavioral phenotypes of Slc6a1-/- mice.

View Article and Find Full Text PDF

Disrupting stroke-induced GAT-1-syntaxin1A interaction promotes functional recovery after stroke.

Cell Rep Med

November 2024

Department of Clinic Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China. Electronic address:

Although stroke is a frequent cause of permanent disability, our ability to promote stroke recovery is limited. Here, we design a small-molecule stroke recovery promoting agent that works by dissociating γ-aminobutyric acid (GABA) transporter 1 (GAT-1) from syntaxin1A (Synt1A), a soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) protein. Stroke induces an increase in GAT-1-Synt1A interaction in the subacute phase, a critical period for functional recovery.

View Article and Find Full Text PDF

patient & organization perspective: founding of SLC6A1 connect, research, and ongoing efforts.

Ther Adv Rare Dis

September 2024

SLC6A1 Connect, 1939 Temperence Hill Drive, Frisco, TX 75034, USA.

Article Synopsis
  • The SLC6A1 Connect organization was founded to support patients and families affected by a specific genetic disorder, providing resources and scientific insights into the condition.
  • Amber Freed started the organization after her son Maxwell was diagnosed with a variant that affects motor development due to issues with the GABA transporter protein.
  • The organization has successfully raised over two million dollars, created a supportive network, and hosts an annual symposium that connects families with researchers and biotech companies to advance treatment options.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!